APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Anorexia-Cachexia Syndrome Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cancer Anorexia-Cachexia Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025198 pages

Choose your research edition.

Industry ResearchCancer Anorexia-Cachexia Syndrome Drug Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Anorexia-Cachexia Syndrome Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Cancer Anorexia-Cachexia Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Anorexia-Cachexia Syndrome Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Anorexia-Cachexia Syndrome Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Cancer Anorexia-Cachexia Syndrome Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cancer Anorexia-Cachexia Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Anorexia-Cachexia Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Anorexia-Cachexia Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cancer Anorexia-Cachexia Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Anorexia-Cachexia Syndrome Drug include Novartis AG, Viking Therapeutics Inc, RaQualia Pharma Inc, PsiOxus Therapeutics Ltd, Obexia AG, Lakewood-Amedex Inc, Incyte Corp, Aphios Corp and Aeterna Zentaris Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Anorexia-Cachexia Syndrome Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Anorexia-Cachexia Syndrome Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Anorexia-Cachexia Syndrome Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Anorexia-Cachexia Syndrome Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Anorexia-Cachexia Syndrome Drug Segment by Company

Novartis AG

Viking Therapeutics Inc

RaQualia Pharma Inc

PsiOxus Therapeutics Ltd

Obexia AG

Lakewood-Amedex Inc

Incyte Corp

Aphios Corp

Aeterna Zentaris Inc

Acacia Pharma Ltd

Cancer Anorexia-Cachexia Syndrome Drug Segment by Type

NEO-1940

Foxo1-nRNA

DLN-101

C-1889

AVGN-7

Others

Cancer Anorexia-Cachexia Syndrome Drug Segment by Application

Hospital

Clinic

Others

Cancer Anorexia-Cachexia Syndrome Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Anorexia-Cachexia Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Anorexia-Cachexia Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Anorexia-Cachexia Syndrome Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Anorexia-Cachexia Syndrome Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Anorexia-Cachexia Syndrome Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cancer Anorexia-Cachexia Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cancer Anorexia-Cachexia Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cancer Anorexia-Cachexia Syndrome Drug Industry Trends Table 2. Cancer Anorexia-Cachexia Syndrome Drug Industry Drivers Table 3. Cancer Anorexia-Cachexia Syndrome Drug Industry Opportunities and Challenges Table 4. Cancer Anorexia-Cachexia Syndrome Drug Industry Restraints Table 5. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Manufacturers Table 9. Global Cancer Anorexia-Cachexia Syndrome Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Cancer Anorexia-Cachexia Syndrome Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cancer Anorexia-Cachexia Syndrome Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cancer Anorexia-Cachexia Syndrome Drug Manufacturers, Product Type & Application Table 13. Global Cancer Anorexia-Cachexia Syndrome Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Anorexia-Cachexia Syndrome Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of NEO-1940 Table 17. Major Manufacturers of Foxo1-nRNA Table 18. Major Manufacturers of DLN-101 Table 19. Major Manufacturers of C-1889 Table 20. Major Manufacturers of AVGN-7 Table 21. Major Manufacturers of Others Table 22. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Type (2021-2026) & (K Units) Table 24. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Type (2027-2032) & (K Units) Table 25. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Type (2021-2026) Table 26. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Type (2027-2032) Table 27. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Type (2021-2026) & (K Units) Table 29. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Type (2027-2032) & (K Units) Table 30. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share by Type (2021-2026) Table 31. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Others Table 35. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Application (2021-2026) & (K Units) Table 37. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Application (2027-2032) & (K Units) Table 38. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Application (2021-2026) Table 39. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Application (2027-2032) Table 40. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Application (2021-2026) & (K Units) Table 42. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Application (2027-2032) & (K Units) Table 43. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share by Application (2021-2026) Table 44. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share by Application (2027-2032) Table 45. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Region (2021-2026) Table 48. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Cancer Anorexia-Cachexia Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 52. North America Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 53. Europe Cancer Anorexia-Cachexia Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 55. Europe Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Cancer Anorexia-Cachexia Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share by Region (2021-2026) Table 66. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share by Region (2027-2032) Table 67. Novartis AG Company Information Table 68. Novartis AG Business Overview Table 69. Novartis AG Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Novartis AG Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 71. Novartis AG Recent Development Table 72. Viking Therapeutics Inc Company Information Table 73. Viking Therapeutics Inc Business Overview Table 74. Viking Therapeutics Inc Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Viking Therapeutics Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 76. Viking Therapeutics Inc Recent Development Table 77. RaQualia Pharma Inc Company Information Table 78. RaQualia Pharma Inc Business Overview Table 79. RaQualia Pharma Inc Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. RaQualia Pharma Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 81. RaQualia Pharma Inc Recent Development Table 82. PsiOxus Therapeutics Ltd Company Information Table 83. PsiOxus Therapeutics Ltd Business Overview Table 84. PsiOxus Therapeutics Ltd Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. PsiOxus Therapeutics Ltd Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 86. PsiOxus Therapeutics Ltd Recent Development Table 87. Obexia AG Company Information Table 88. Obexia AG Business Overview Table 89. Obexia AG Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Obexia AG Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 91. Obexia AG Recent Development Table 92. Lakewood-Amedex Inc Company Information Table 93. Lakewood-Amedex Inc Business Overview Table 94. Lakewood-Amedex Inc Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Lakewood-Amedex Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 96. Lakewood-Amedex Inc Recent Development Table 97. Incyte Corp Company Information Table 98. Incyte Corp Business Overview Table 99. Incyte Corp Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Incyte Corp Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 101. Incyte Corp Recent Development Table 102. Aphios Corp Company Information Table 103. Aphios Corp Business Overview Table 104. Aphios Corp Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Aphios Corp Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 106. Aphios Corp Recent Development Table 107. Aeterna Zentaris Inc Company Information Table 108. Aeterna Zentaris Inc Business Overview Table 109. Aeterna Zentaris Inc Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Aeterna Zentaris Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 111. Aeterna Zentaris Inc Recent Development Table 112. Acacia Pharma Ltd Company Information Table 113. Acacia Pharma Ltd Business Overview Table 114. Acacia Pharma Ltd Cancer Anorexia-Cachexia Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Acacia Pharma Ltd Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio Table 116. Acacia Pharma Ltd Recent Development Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Cancer Anorexia-Cachexia Syndrome Drug Distributors List Table 120. Cancer Anorexia-Cachexia Syndrome Drug Customers List Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. Cancer Anorexia-Cachexia Syndrome Drug Product Image Figure 2. Global Cancer Anorexia-Cachexia Syndrome Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Anorexia-Cachexia Syndrome Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Anorexia-Cachexia Syndrome Drug Sales (2021-2032) & (K Units) Figure 5. Global Cancer Anorexia-Cachexia Syndrome Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cancer Anorexia-Cachexia Syndrome Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. NEO-1940 Image Figure 9. Foxo1-nRNA Image Figure 10. DLN-101 Image Figure 11. C-1889 Image Figure 12. AVGN-7 Image Figure 13. Others Image Figure 14. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Type (2021-2032) Figure 17. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Application (2021-2032) Figure 26. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Country (2021-2032) Figure 43. China Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Cancer Anorexia-Cachexia Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Cancer Anorexia-Cachexia Syndrome Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Cancer Anorexia-Cachexia Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Cancer Anorexia-Cachexia Syndrome Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Cancer Anorexia-Cachexia Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Cancer Anorexia-Cachexia Syndrome Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Cancer Anorexia-Cachexia Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Cancer Anorexia-Cachexia Syndrome Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Cancer Anorexia-Cachexia Syndrome Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • NEO-1940
  • Foxo1-nRNA
  • DLN-101
  • C-1889
  • AVGN-7
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Viking Therapeutics Inc
  • RaQualia Pharma Inc
  • PsiOxus Therapeutics Ltd
  • Obexia AG
  • Lakewood-Amedex Inc
  • Incyte Corp
  • Aphios Corp
  • Aeterna Zentaris Inc
  • Acacia Pharma Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cancer Anorexia-Cachexia Syndrome Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cancer Anorexia-Cachexia Syndrome Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cancer Anorexia-Cachexia Syndrome Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cancer Anorexia-Cachexia Syndrome Drug Market Dynamics
  1. 2.1 Cancer Anorexia-Cachexia Syndrome Drug Industry Trends
  2. 2.2 Cancer Anorexia-Cachexia Syndrome Drug Industry Drivers
  3. 2.3 Cancer Anorexia-Cachexia Syndrome Drug Industry Opportunities and Challenges
  4. 2.4 Cancer Anorexia-Cachexia Syndrome Drug Industry Restraints
3 Cancer Anorexia-Cachexia Syndrome Drug Market by Manufacturers
  1. 3.1 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cancer Anorexia-Cachexia Syndrome Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cancer Anorexia-Cachexia Syndrome Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Anorexia-Cachexia Syndrome Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cancer Anorexia-Cachexia Syndrome Drug Manufacturers, Product Type & Application
  7. 3.7 Global Cancer Anorexia-Cachexia Syndrome Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Anorexia-Cachexia Syndrome Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Anorexia-Cachexia Syndrome Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Anorexia-Cachexia Syndrome Drug Tier 1, Tier 2, and Tier 3
4 Cancer Anorexia-Cachexia Syndrome Drug Market by Type
  1. 4.1 Cancer Anorexia-Cachexia Syndrome Drug Type Introduction
  2. 4.1.1 NEO-1940
  3. 4.1.2 Foxo1-nRNA
  4. 4.1.3 DLN-101
  5. 4.1.4 C-1889
  6. 4.1.5 AVGN-7
  7. 4.1.6 Others
  8. 4.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Type
  9. 4.2.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Type (2021-2032)
  11. 4.2.3 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Type (2021-2032)
  12. 4.3 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Type
  13. 4.3.1 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Type (2021-2032)
  15. 4.3.3 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share by Type (2021-2032)
5 Cancer Anorexia-Cachexia Syndrome Drug Market by Application
  1. 5.1 Cancer Anorexia-Cachexia Syndrome Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Application
  6. 5.2.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Application
  10. 5.3.1 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share by Application (2021-2032)
6 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Region
  1. 6.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Anorexia-Cachexia Syndrome Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Cancer Anorexia-Cachexia Syndrome Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cancer Anorexia-Cachexia Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cancer Anorexia-Cachexia Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cancer Anorexia-Cachexia Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cancer Anorexia-Cachexia Syndrome Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Region
  1. 7.1 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Region
  2. 7.1.1 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Cancer Anorexia-Cachexia Syndrome Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cancer Anorexia-Cachexia Syndrome Drug Revenue (2021-2032)
  8. 7.2.2 North America Cancer Anorexia-Cachexia Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cancer Anorexia-Cachexia Syndrome Drug Revenue (2021-2032)
  11. 7.3.2 Europe Cancer Anorexia-Cachexia Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cancer Anorexia-Cachexia Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cancer Anorexia-Cachexia Syndrome Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cancer Anorexia-Cachexia Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Cancer Anorexia-Cachexia Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Viking Therapeutics Inc
  8. 8.2.1 Viking Therapeutics Inc Company Information
  9. 8.2.2 Viking Therapeutics Inc Business Overview
  10. 8.2.3 Viking Therapeutics Inc Cancer Anorexia-Cachexia Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Viking Therapeutics Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  12. 8.2.5 Viking Therapeutics Inc Recent Developments
  13. 8.3 RaQualia Pharma Inc
  14. 8.3.1 RaQualia Pharma Inc Company Information
  15. 8.3.2 RaQualia Pharma Inc Business Overview
  16. 8.3.3 RaQualia Pharma Inc Cancer Anorexia-Cachexia Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 RaQualia Pharma Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  18. 8.3.5 RaQualia Pharma Inc Recent Developments
  19. 8.4 PsiOxus Therapeutics Ltd
  20. 8.4.1 PsiOxus Therapeutics Ltd Company Information
  21. 8.4.2 PsiOxus Therapeutics Ltd Business Overview
  22. 8.4.3 PsiOxus Therapeutics Ltd Cancer Anorexia-Cachexia Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 PsiOxus Therapeutics Ltd Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  24. 8.4.5 PsiOxus Therapeutics Ltd Recent Developments
  25. 8.5 Obexia AG
  26. 8.5.1 Obexia AG Company Information
  27. 8.5.2 Obexia AG Business Overview
  28. 8.5.3 Obexia AG Cancer Anorexia-Cachexia Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Obexia AG Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  30. 8.5.5 Obexia AG Recent Developments
  31. 8.6 Lakewood-Amedex Inc
  32. 8.6.1 Lakewood-Amedex Inc Company Information
  33. 8.6.2 Lakewood-Amedex Inc Business Overview
  34. 8.6.3 Lakewood-Amedex Inc Cancer Anorexia-Cachexia Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lakewood-Amedex Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  36. 8.6.5 Lakewood-Amedex Inc Recent Developments
  37. 8.7 Incyte Corp
  38. 8.7.1 Incyte Corp Company Information
  39. 8.7.2 Incyte Corp Business Overview
  40. 8.7.3 Incyte Corp Cancer Anorexia-Cachexia Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Incyte Corp Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  42. 8.7.5 Incyte Corp Recent Developments
  43. 8.8 Aphios Corp
  44. 8.8.1 Aphios Corp Company Information
  45. 8.8.2 Aphios Corp Business Overview
  46. 8.8.3 Aphios Corp Cancer Anorexia-Cachexia Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Aphios Corp Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  48. 8.8.5 Aphios Corp Recent Developments
  49. 8.9 Aeterna Zentaris Inc
  50. 8.9.1 Aeterna Zentaris Inc Company Information
  51. 8.9.2 Aeterna Zentaris Inc Business Overview
  52. 8.9.3 Aeterna Zentaris Inc Cancer Anorexia-Cachexia Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Aeterna Zentaris Inc Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  54. 8.9.5 Aeterna Zentaris Inc Recent Developments
  55. 8.10 Acacia Pharma Ltd
  56. 8.10.1 Acacia Pharma Ltd Company Information
  57. 8.10.2 Acacia Pharma Ltd Business Overview
  58. 8.10.3 Acacia Pharma Ltd Cancer Anorexia-Cachexia Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Acacia Pharma Ltd Cancer Anorexia-Cachexia Syndrome Drug Product Portfolio
  60. 8.10.5 Acacia Pharma Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Anorexia-Cachexia Syndrome Drug Value Chain Analysis
  2. 9.1.1 Cancer Anorexia-Cachexia Syndrome Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Anorexia-Cachexia Syndrome Drug Production Mode & Process
  6. 9.2 Cancer Anorexia-Cachexia Syndrome Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Anorexia-Cachexia Syndrome Drug Distributors
  9. 9.2.3 Cancer Anorexia-Cachexia Syndrome Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst